HC Wainwright Issues Optimistic Estimate for RCUS Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Investment analysts at HC Wainwright lifted their Q1 2026 EPS estimates for shares of Arcus Biosciences in a report released on Thursday, February 26th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($1.01) for the quarter, up from their previous estimate of ($1.18). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($4.66) EPS, FY2027 earnings at ($3.62) EPS, FY2028 earnings at ($2.26) EPS and FY2029 earnings at ($0.71) EPS.

Several other equities research analysts have also recently commented on the company. Truist Financial set a $30.00 target price on Arcus Biosciences in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, January 21st. Wells Fargo & Company set a $23.00 price objective on Arcus Biosciences and gave the stock an “equal weight” rating in a report on Thursday, February 12th. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $20.00 price target (down from $23.00) on shares of Arcus Biosciences in a research report on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Arcus Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $29.33.

Arcus Biosciences Stock Performance

RCUS stock opened at $20.36 on Monday. The company has a 50 day moving average price of $21.57 and a 200 day moving average price of $18.56. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $26.40. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.36 and a quick ratio of 4.36. The stock has a market capitalization of $2.55 billion, a PE ratio of -6.17 and a beta of 0.85.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Wednesday, February 25th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.22. The company had revenue of $33.00 million for the quarter, compared to analyst estimates of $24.94 million. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 65.77%. Arcus Biosciences’s quarterly revenue was down 8.3% on a year-over-year basis. During the same period in the prior year, the business earned ($1.03) earnings per share.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 6,552 shares of the stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $23.38, for a total value of $153,185.76. Following the completion of the sale, the chief financial officer directly owned 67,924 shares in the company, valued at $1,588,063.12. This represents a 8.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Juan C. Jaen sold 31,823 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $21.41, for a total value of $681,330.43. Following the sale, the president directly owned 922,240 shares of the company’s stock, valued at approximately $19,745,158.40. The trade was a 3.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 263,987 shares of company stock valued at $6,025,620. Corporate insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

Large investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. raised its position in Arcus Biosciences by 121.9% in the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after buying an additional 881 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Arcus Biosciences in the fourth quarter valued at $39,000. GAMMA Investing LLC grew its holdings in Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after purchasing an additional 1,021 shares during the period. SBI Securities Co. Ltd. boosted its stake in shares of Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares during the period. Finally, Abich Financial Wealth Management LLC bought a new position in Arcus Biosciences during the third quarter worth $69,000. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences News Roundup

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analysts’ aggregate view remains constructive — Arcus received an average recommendation of “Moderate Buy” from the analyst community, which supports investor demand. Arcus Receives Average Recommendation
• Positive Sentiment: HC Wainwright raised several near‑term and later‑year estimates (Q1 and Q2 2026 EPS were revised up; FY2028 and FY2029 loss forecasts improved) and reiterated a Buy rating with a $32 price target — that retained Buy conviction can buoy the stock despite mixed cuts elsewhere. MarketBeat RCUS
• Neutral Sentiment: Wall Street Zen upgraded Arcus to a Hold — an incremental change in street coverage that may temper volatility but is not an outright positive endorsement. Arcus Upgraded to Hold
• Neutral Sentiment: Analysts published longer‑range forecasts (FY2030 coverage), adding modelling detail for investors but without an immediate clear directional impact. Analysts Issue FY2030 Forecasts
• Negative Sentiment: Offsetting the positives, HC Wainwright increased loss projections for FY2026 (now -$4.66 vs. prior -$4.00) and raised Q3/Q4 2026 loss estimates — these larger near‑term losses are a negative earnings surprise risk and could weigh on sentiment if cash burn or trial timelines disappoint. HC Wainwright Estimate Changes

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.